Authors
Latest:
Addressing Fatigue as an Adverse Event in Ovarian and Uterine CancersHanneke Poort, PhD, discusses research regarding fatigue as an adverse event in patients with gynecologic cancer.
Latest:
Dr. Kolberg on Collecting Real-World Biosimilar Trastuzumab Data in Breast CancerHans-Christian Kolberg, MD, discusses collecting real-world data for biosimilars, specifically the trastuzumab biosimilar ABP 980 for breast cancer.
Latest:
Future Outlooks in the Treatment of Advanced RCCExperts close the discussion by sharing insights on the future in advanced RCC, emphasizing the development of emerging agents and combination regimens for the treatment landscape.
Latest:
Multidisciplinary Strategies in RCC Management: Future Directions in CareClosing out their discussion on renal cell carcinoma, key opinion leaders highlight the value of multidisciplinary care and look toward future evolutions in the treatment paradigm.
Latest:
Dr. Schmoll on the Toxicity of the CHARTA Study in CRCHans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/Oncology, University Hospital Halle, discusses the toxicity of the CHARTA study for patients with colorectal cancer (CRC).
Latest:
Dr. Raftopoulos on Pulmonary Toxicity With EGFR TKIsHaralambos Raftopoulos, MD, associate professor, Hofstra North Shore-LIJ School of Medicine, discusses pulmonary toxicity with EGFR tyrosine kinase inhibitors (TKIs).
Latest:
Dr Nakshatri on the Investigation of TONSL in Breast CancersHarikrishna Nakshatri, BVSc, PhD, discusses the investigation of TONSL in patients with breast cancer.
Latest:
Dr. Harvey Discusses Preventing Breast CancerDr. Harold Harvey from Penn State Hershey Cancer Institute Discusses Preventing Breast Cancer
Latest:
HR+/HER2- Breast Cancer: Excitement for Upcoming Clinical Trial ReadoutsKey opinion leaders in breast cancer management share their excitement for data that will be released at the annual ASCO meeting in 2022 or the near future.
Latest:
Dr. Burstein on the Treatment Landscape of HER2+ Breast CancerHarold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the treatment landscape of HER2-positive breast cancer.
Latest:
Dr. Freeman Describes Patient NavigationDr. Harold P. Freeman from Ralph Lauren Center for Cancer Care and Prevention Describes Patient Navigation
Latest:
Dr Kluger on the FDA Approval of Lifileucel in Advanced MelanomaHarriet Kluger, MD, discusses the FDA approval of the tumor infiltrating lymphocyte therapy lifileucel for patients with advanced melanoma.
Latest:
The Role of Genetic Profiling in Secondary AMLJames K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
Latest:
Final Thoughts on New Developments and Emerging AgentsPanelists conclude by reviewing possible advancements on the horizon in AML such as the potential emergence of Menin inhibitors and bispecific T-cell engagers as well as improved methods for predicting response and preventing relapse.
Latest:
A Look Towards the Future of ESCCClosing out their conversation, Drs Saba and Yoon share their hopes for the future of ESCC, including elucidating the molecular mechanisms behind immune evasion and treatment response to chemotherapy, radiation, and immunotherapy.
Latest:
The Role of Venetoclax for Treatment of AMLRenowned experts in hematology-oncology provide insight into the practical implications of treating acute myeloid leukemia with the current standard-of-care regimen using venetoclax.
Latest:
Dr. Ranganath on Treatment Considerations in Nonmetastatic Prostate CancerHarsha Ranganath, MD, a fellow in the Division of Hematology & Oncology at the University of Tennessee West Cancer Center, discusses treatment considerations in nonmetastatic prostate cancer.
Latest:
Dr. Harvey I. Pass on Personalized Surgical Approaches in Lung CancerHarvey I. Pass, MD, director, Thoracic Surgery, Thoracic Oncology, NYU Langone Medical Center, discusses what it means to take a personalized approach to surgery in lung cancer.
Latest:
Dr. Hashem El-Serag on the Relationship Between NASH and HCCHashem El-Serag, MD, MPH, medicine-gastroenterology, Baylor College of Medicine, discusses the relationship between nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).
